Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Scientists identify regulatory T cells responsible for limiting immune response

Scientists from the Walter and Eliza Hall Institute have identified the key immune cell population responsible for regulating the body's immune response.

6 Mar 2011

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

Pfizer Inc. today announced that the ORAL Sync Phase 3 study of tofacitinib, formerly known as tasocitinib, an investigational, novel, oral JAK inhibitor, being studied in moderate-to-severe rheumatoid arthritis, met its primary endpoints by showing statistically significant changes versus placebo in reducing signs and symptoms of RA, as measured by ACR20 response rates at six months; in improving physical function, as measured by mean change in HAQ DI at three months; and in reaching DAS28-4 <2.6 at six months.

5 Mar 2011

NorthShore receives $1.5 million gift to establish center for the study of complex diseases

NorthShore University HealthSystem (NorthShore) Foundation has received a $1.5 million gift for the creation of the Center for the Study of Complex Diseases. The development of the Center, which is being established within the NorthShore Research Institute, is made possible through a generous gift by Mr. and Mrs. Richard L. Keyser of Glencoe, Ill., through the Keyser Family Research Fund.

4 Mar 2011

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

Pluristem Therapeutics, Inc. and the Berlin-Brandenburg Center for Regenerative Therapies (BCRT), in cooperation with the Charite - University of Medicine in Berlin,today announced the results of a pre-clinical study demonstrating that the local administration of PLX cells following muscle injury resulted in significant improvement in the recovery of muscle function when compared with the control group. This

2 Mar 2011

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

4SC AG, a drug discovery and development company focused on autoimmune and cancer indications, announces the final data from the ENTRANCE Phase IIa trial in inflammatory bowel disease with vidofludimus, an oral inhibitor of interleukin-17 release and DHODH, including the secondary endpoints comprising the analysis of CDAI and CAI disease scores, change of prednisolone intake and threshold doses, safety, pharmacokinetics and biomarkers.

28 Feb 2011

Researchers identify probiotic bacterial strain that may treat ulcers caused by H. pylori

Researchers from Spain have identified a strain of probiotic bacteria that may be useful in treating ulcers caused by Helicobacter pylori. They report their findings in the February 2011 issue of the journal Applied and Environmental Microbiology.

25 Feb 2011

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.

23 Feb 2011

New study: Asthma may have relationship with airway microbiota composition

Asthma may have a surprising relationship with the composition of the species of bacteria that inhabit bronchial airways, a finding that could suggest new treatment or even potential cures for the common inflammatory disease, according to a new UCSF-led study.

18 Feb 2011

Blocking interleukin 15 may help restore oral tolerance to gluten

Blocking a factor that can activate the human immune response against intestinal bacteria or certain foods could prevent the development of celiac disease in those most at risk, researchers report in the journal Nature.

11 Feb 2011

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

A three-year, $3 million gift from the Richard J. Fasenmyer Foundation will fund research by a pair of Cleveland physicians into HIV and the body's response in autoimmune diseases.

11 Feb 2011

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Medical researchers from The University of Texas Health Science Center at Houston (UTHealth) presented new research results at the American Heart Association International Stroke Conference that demonstrated how MultiStem-, a novel stem cell therapy being developed by Athersys, Inc. provided multiple benefits when administered in preclinical models of ischemic stroke.

11 Feb 2011

Athersys enters definitive agreements to sell common stock, warrants

Athersys, announced today that it has entered into definitive agreements with certain investors to sell 4,366,667 shares of its common stock and warrants to purchase up to an additional 1,310,000 shares of common stock in a registered direct offering for gross proceeds of approximately $13.1 million, before deducting fees and offering expenses.

29 Jan 2011

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

ChemoCentryx, today announced the initiation of a Phase I clinical trial of CCX832, an orally-administered small molecule that is a potent and selective inhibitor of the chemoattractant receptor, ChemR23.

26 Jan 2011

Mystery of 'inactive' defensin solved

Under standard laboratory conditions, the human beta-defensin 1 (hBD-1), a human antibiotic naturally produced in the body, had always shown only little activity against microbes. Nevertheless the human body produces it in remarkable quantities.

24 Jan 2011

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

FibroGen, today announced interim results of a phase 1/2 trial of FG-3019, a therapeutic antibody against connective tissue growth factor, in combination with gemcitabine and erlotinib in individuals with unresectable pancreatic cancer.

23 Jan 2011

Study validates MultiStem as potential stem cell therapy for spinal cord injury

Case Western Reserve University School of Medicine and Athersys, Inc. announced a joint scientific study on spinal cord injury will be published today in the January issue of The Journal of Neuroscience.

20 Jan 2011

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

4SC AG, a drug discovery and development company, today announced that the first patient has been dosed in the Phase I/II SHORE study with the oral pan-histone deacetylase (HDAC) inhibitor resminostat as a second-line treatment for patients with advanced and metastatic colorectal KRAS-mutant cancer.

20 Jan 2011

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.

19 Jan 2011

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

19 Jan 2011

New findings show reduced vitamin D absorption in patients with quiescent CD

Researchers from Boston University School of Medicine have for the first time shown that reduced vitamin D absorption in patients with quiescent Crohn's disease may be the cause for their increased risk for vitamin D deficiency.

19 Jan 2011

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

Scientists identify regulatory T cells responsible for limiting immune response

Pfizer's ORAL Sync Phase 3 study of tofacitinib in moderate-to-severe RA meets primary endpoints

NorthShore receives $1.5 million gift to establish center for the study of complex diseases

Pluristem's PLX cells exhibit potential to treat accidental and intentionally induced muscle injuries

Final data from 4SC vidofludimus ENTRANCE Phase IIa trial against IBD presented at ECCO IBD Conference

Researchers identify probiotic bacterial strain that may treat ulcers caused by H. pylori

USPTO issues patent to Synergy's SP-333 for treatment of IBD

New study: Asthma may have relationship with airway microbiota composition

Blocking interleukin 15 may help restore oral tolerance to gluten

Richard J. Fasenmyer Foundation awards $3M to Cleveland physicians for AIDS research

Athersys' MultiStem cell therapy provides multiple benefits in preclinical models of ischemic stroke

Athersys enters definitive agreements to sell common stock, warrants

ChemoCentryx commences CCX832 Phase I trial in patients with psoriasis

Mystery of 'inactive' defensin solved

FibroGen announces FG-3019 interim results from phase 1/2 trial against pancreatic cancer

Study validates MultiStem as potential stem cell therapy for spinal cord injury

4SC initiates dosing in resminostat Phase I/II SHORE study for KRAS-mutant colorectal cancer

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Case Western Reserve, Athersys enter partnership for scientific study on spinal cord injury

New findings show reduced vitamin D absorption in patients with quiescent CD

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Inflammatory Bowel Disease News and Research

Latest Inflammatory Bowel Disease News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in